Breast cancer study results impressed at this year’s meeting, but raised new questions. Doctors also wrestled with how best ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

Unlike Soliris, Ultomiris has significant competitive advantages, including less frequent injections [every 2 ... Among its blockbusters, I highlight Imfinzi, Calquence, Enhertu, Imjudo, and ...

Three more fake batches of the cancer immunotherapy have been encountered in Iran and Türkiye, warns the agency.

AstraZeneca PLC (LSE/STO/Nasdaq:LON:AZN) announced today that its drug Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) as a treatment for adult patients with ...

AstraZeneca (AZ) has announced that its Imfinzi (durvalumab)-based perioperative regimen has been recommended for approval by the European Medicines Agency’s human medicines committee to treat adults ...